Navigation Links
Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment
Date:11/7/2007

- Renal Solutions Announces Opportunity for Patients to Participate in

Research Aiming Toward Improved Future Dialysis Options -

WARRENDALE, Pa., Nov. 7 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services, today announced that a home use clinical research trial has begun using sorbent technology. The study presents the opportunity for 25 dialysis study participants to evaluate the ability to self-administer extended duration dialysis in the home when using the Allient(R) Sorbent Hemodialysis System. In this study, the use of the Allient System in the home is an investigational use.

The Allient System enables hemodialysis using only 1.5 gallons (6 liters) of drinking water to provide a convenient therapy option requiring no plumbing modifications to a person's home. It is the only system that uses Sorbent Management for Advanced Renal Replacement Therapy (SMARRT(TM)). SMARRT therapy is based on more than 35 years of proven dialysis, using a gentle, patient-driven technology that enables flexible treatment options including extended duration dialysis therapy -- resulting in greater patient freedom and control.

"Our current participating clinical trial sites demonstrate their commitment to improving future patients' quality of life by taking part in a study like this," said David Vanella, Renal Solutions Vice President of Regulatory Affairs. "It's the drive to discover and apply new technologies that ultimately makes future alternative therapies available and accessible to patients."

The success of this trial may permit dialysis providers in the future to offer an alternative system and therapeutic modality to their patients. In the trial, study participants are trained and transitioned during the initial 8 weeks from self-care in a dialysis clinic setting to 8 weeks of dialysis self- administration in the home.

"Extended duration dialysis in the home is not a new concept and its potential benefits are well-known, including increased stamina, enhanced appetite and improved quality of life as just a few of the improvements this form of treatment can offer," said Renal Solutions CEO Peter M. DeComo. "The home modality has been out of vogue in part because available dialysis equipment hasn't been suited to the home. But it's on its way back. This trial may mark a tremendous step forward for people living with chronic kidney failure in the future."

"In addition to home hemodialysis being a proven alternative to in-center dialysis, at-home dialysis offers individuals more freedom and control in their lives," said Dr. Mark Rohrscheib, University of New Mexico Health Sciences Center. "The convenience of a dialysis technology that uses only a small amount of drinking water for each treatment is a tremendous advantage for home dialysis. Patients interested in new modalities will be excited to learn about this trial."

"We're pleased to be part of a trial that may introduce new options for our home dialysis patients," said Brigitte Schiller, MD, Director of Research, Satellite Healthcare, Mountain View, Ca. "This trial may further bring to light the benefits of extended duration dialysis."

Active recruitment has begun at multiple sites with subjects continuing to enroll in the study. Renal Solutions is working with a group of nephrologists and patient-focused dialysis facilities to conduct this trial. Individuals who are interested in contributing to a movement that is intended innovate the way chronic kidney failure is treated should ask their doctors about participating local research sites.

Patient-focused dialysis centers with certified home programs that are interested in learning more about this home trial should contact Mr. Vanella, (724) 772-6900, ext. 140.

About Renal Solutions, Inc.

Renal Solutions, Inc., a medical device and healthcare service company, is commercializing the Allient(R) Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System, brings SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) therapy to the dialysis field, opening new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased flexibility and convenience benefits.


'/>"/>
SOURCE Renal Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clinical trials present better alternatives for dialysis patients
2. Nighttime Home Dialysis a Boon for Kidney Patients
3. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
4. WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA
5. New peritoneal dialysis diagnostic discovered
6. Early intervention dramatically improves outcomes for new dialysis patients
7. Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date
8. Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
9. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
10. DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead
11. Radiologists encouraged to look beyond cancer for clinically unseen diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
(Date:6/23/2016)...  The National Pharmaceutical Council (NPC) today announced ... research organization as its newest member.  ... president and chief scientific officer, Mallinckrodt Pharmaceuticals, will ... Board of Directors. ... us in support of our efforts to conduct ...
Breaking Medicine Technology: